20n Bio aims to leverage advanced high throughput screening techniques

20n Bio aims to leverage advanced high−throughput screening techniques and computational tools to develop peptide drugs with precise biophysical, functional, and pharmacological properties. The company’s focus is on creating effective and targeted treatments for various diseases, particularly those that have been challenging to treat with traditional small molecule or biologic drugs. Cyclic peptides are a unique class of therapeutics known for their stability, specificity, and ability to modulate challenging targets. These peptides form a circular structure, which can enhance their binding affinity and resistance to degradation, making them ideal candidates for drug development.